Performant Healthcare, Inc. (PHLT) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a positive sentiment with increased revenue and adjusted EBITDA guidance, strong revenue growth, and positive cash flow. While there are risks like regulatory issues and competitive pressures, the company's strategic initiatives, such as Project Turing and New York State Medicaid RAC implementation, are expected to drive efficiency and revenue. The lack of a share repurchase program is a slight negative, but overall, the positive outlook and improved financial metrics suggest a stock price increase in the 2% to 8% range.
Key Financial Performance
Total Revenue $33.3 million, up 22% year-over-year. Excluding $1.5 million of customer care revenue from the prior year, revenue grew almost 30%.
Claims Auditing Revenue $17.1 million, up 38% year-over-year, driven by new business wins and scaling operations.
Eligibility Revenue $16.1 million, up 20% year-over-year, with significant contributions from commercial clients and operationalizing key partnerships.
Adjusted EBITDA $3.3 million, compared to an adjusted EBITDA loss of $1.2 million in Q1 2024, driven by strong revenue growth and efficiency gains.
Cash Flow Positive $1.4 million, compared to a negative $3.6 million in the prior year quarter, reflecting improved operational performance.
Operating Expenses $33 million, up $2 million year-over-year, primarily due to spending on new implementations and technology investments.
Annualized Revenue from New Implementations Expected to deliver $4.5 million to $5 million at steady state from 13 commercial programs implemented in Q1.
Adjusted EBITDA Guidance Increased to $9 million to $10 million for the full year, more than doubling 2024 adjusted EBITDA.
Full-Year Revenue Guidance Raised to a range of $133 million to $135 million, reflecting strong first quarter performance.
Operating Highlights
Eligibility Revenue Growth: Eligibility revenue for the quarter was $16.1 million, representing an increase of roughly 20% year-over-year.
New Implementations: Implemented 13 commercial programs in Q1 2025, expected to deliver $4.5 million to $5 million in annualized revenue at steady state.
Project Turing: Integrating AI and natural language processing technologies to streamline processes and improve efficiency.
New York State Medicaid RAC Implementation: Commenced early in Q2 2025, expected to generate double-digit annualized revenue at steady state.
Commercial Market Expansion: Continued expansion of the commercial pipeline, with a focus on client-centric partnerships.
Adjusted EBITDA: Positive adjusted EBITDA of $3.3 million in Q1 2025, compared to a loss of $1.2 million in Q1 2024.
Operating Expenses: Operating expenses were about $33 million, primarily driven by spending to operationalize new implementations.
Full-Year Guidance Increase: Revenue guidance raised to $133 million to $135 million, and adjusted EBITDA guidance increased to $9 million to $10 million.
Focus on Cost Management: Disciplined focus on cost management contributing to improved profitability.
Risk or Challenges
Regulatory Issues: Performant was not selected in the recent CMS RAC RFP for Regions 3 through 5, which represented net new opportunities. This could impact future revenue growth from government contracts.
Supply Chain Challenges: The company does not expect material impact from tariff pressures as their revenue is 100% domestic and their expense structure does not rely on foreign goods or services.
Economic Factors: The healthcare industry is at a critical inflection point, with rising costs and complexities. The demand for healthcare payment integrity services is urgent, which could affect operational strategies.
Competitive Pressures: Performant aims to lead in the eligibility space, competing against long-standing legacy vendors. The need for continuous innovation and client-centric solutions is critical to maintain market position.
Implementation Risks: The company anticipates a temporary dip in commercial implementations due to reallocating resources for the New York State RAC contract, which may affect short-term revenue.
Guidance & Outlook
Healthcare Revenue Growth: 29% healthcare revenue growth compared to Q1 2024.
Adjusted EBITDA: Positive adjusted EBITDA of over $3 million, a significant improvement from a loss of $1.2 million in Q1 2024.
Commercial Programs Implemented: Implemented 13 commercial programs in Q1 2025, expected to contribute $4.5 million to $5 million in annualized revenue.
New York State Medicaid RAC Implementation: Commenced early in Q2 2025, anticipated to generate double-digit annualized revenue at steady state.
Project Turing: Focus on integrating AI and natural language processing to improve efficiency and accuracy.
Full-Year Revenue Guidance: Increased to a range of $133 million to $135 million.
Adjusted EBITDA Guidance: Increased to $9 million to $10 million, more than doubling 2024 adjusted EBITDA.
Quarterly Adjusted EBITDA Cadence: More weighted to the first and fourth quarters due to the wind down of RAC Region 5.
Free Cash Flow Generation: Anticipate positive free cash flow generation by the end of 2025.
Shareholder Return Plan
Share Repurchase Program: None
Key Q&A
Earnings Word Cloud
PHLT Transcript
The earnings call indicates a positive sentiment with increased revenue and adjusted EBITDA guidance, strong revenue growth, and positive cash flow. While there are risks like regulatory issues and competitive pressures, the company's strategic initiatives, such as Project Turing and New York State Medicaid RAC implementation, are expected to drive efficiency and revenue. The lack of a share repurchase program is a slight negative, but overall, the positive outlook and improved financial metrics suggest a stock price increase in the 2% to 8% range.
The earnings call summary shows positive financial growth and strategic initiatives, such as healthcare revenue growth and technology advancements. However, the Q&A section reveals management's inability to provide clear answers on client churn and political impacts, raising concerns. Although the company forecasts revenue growth and aims for profitability, the presence of regulatory, competitive, and operational risks tempers enthusiasm. The share repurchase plan is positive, but investment risks could suppress short-term profitability. Overall, the mixed signals and uncertainties justify a neutral sentiment.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
